Actinogen Medical Ltd has released a press release.
ACW XanaCIDD depression trial results expected early August
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Positive Xanamem biomarker trial published in Jnl Alz Dis
- ACW Oversubscribed $3.9 million entitlement offer completed
- Actinogen entitlement offer closed and oversubscribed
- Prospectus - Non-renounceable Entitlement Offer
- Actinogen announces capital raising of up to $8.9 million
Later from Actinogen Medical
- ACW June 2024 quarterly activity report & Appendix 4C
- ACW XanaCIDD phase 2a trial topline results
- ACW updated depression trial results and implications
- ACW Appendix 4E and 2024 Annual Report
- ACW FY2024 results, advancing into late-stage trials
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical